Syndax Pharmaceuticals Inc (FRA:1T3) Stock News, Headlines & Updates
Syndax Pharmaceuticals Inc Stock News from GuruFocus
- 1
Aug 12, 2024
Syndax Announces Publication in the Journal of Clinical Oncology of Data from the Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia
PRNewswire • 7:00am
Aug 05, 2024
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
PRNewswire • 4:00pm
Aug 01, 2024
Syndax Reports Second Quarter 2024 Financial Results and Provides Clinical and Business Update
PRNewswire • 4:01pm
Jul 29, 2024
Syndax Announces PDUFA Action Date Extension for Revumenib NDA for Relapsed or Refractory KMT2Ar Acute Leukemia
PRNewswire • 7:00am
Jul 25, 2024
Syndax to Announce Second Quarter 2024 Financial Results and Host Conference Call and Webcast on August 1, 2024
PRNewswire • 7:00am
Jul 05, 2024
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
PRNewswire • 4:00pm
Jun 17, 2024
Acute Myeloid Leukemia is on the Rise as Biotechs Race to Develop Groundbreaking Therapies
Marketwired • 8:00am
Jun 14, 2024
Syndax Presents Updated Positive Data from BEAT AML and AUGMENT-102 Phase 1/2 Combination Trials of Revumenib in Patients with Acute Leukemias at EHA 2024 Congress
PRNewswire • 7:00am
Jun 06, 2024
Syndax Announces Plans to Advance into Phase 1b Portion of Trial Evaluating Revumenib in Relapsed or Refractory Metastatic MSS CRC
PRNewswire • 7:00am
Jun 05, 2024
Syndax Announces Participation at the Goldman Sachs 45th Annual Global Healthcare Conference
PRNewswire • 7:00am
Jun 03, 2024
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
PRNewswire • 4:00pm
- 1
Show
Entries
Headlines
Total 0- 1
No recent news